TWSTHealthcare · BiotechnologyThe 13 Wall Street analysts covering Twist Bioscience Corp. hold a median 12-month price target of $189 — +17.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 26 Oct 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Twist Bioscience Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (92): The shares have been drifting up relative to others.
Volatility (26): The share price moves around a lot.
Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on TWST, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +17.9% from it.
Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Oct 2026 | TD Cowen | Maintains | Buy | $115 → $190 |
| 12 Oct 2026 | Canaccord Genuity | Maintains | Buy | $120 → $205 |
| 8 Oct 2026 | Jefferies | Initiates | Hold | $150 |
| 7 Oct 2026 | Barclays | Maintains | Overweight | $112 → $215 |
| 1 Oct 2026 | Guggenheim | Maintains | Buy | — |
| 1 Oct 2026 | Guggenheim | Maintains | Buy | $107 → $212 |
| 29 Sept 2026 | Leerink Partners | Maintains | Outperform | — |
| 29 Sept 2026 | Leerink Partners | Maintains | Outperform | $160 → $190 |
| 18 Sept 2026 | BWS Financial | Maintains | Sell | $45 |
| 18 Sept 2026 | BWS Financial | Maintains | Sell | — |
| 17 Sept 2026 | Leerink Partners | Maintains | Outperform | $120 → $160 |
| 17 Sept 2026 | Leerink Partners | Maintains | Outperform | — |
| 9 Sept 2026 | BWS Financial | Initiates | Sell | — |
| 9 Sept 2026 | BWS Financial | Initiates | Sell | $45 |
| 9 Sept 2026 | UBS | Initiates | Neutral | — |
| 9 Sept 2026 | UBS | Initiates | Neutral | $144 |
| 5 Aug 2026 | Piper Sandler | Maintains | Overweight | $85 → $115 |
| 5 Aug 2026 | Piper Sandler | Maintains | Overweight | — |
| 4 Aug 2026 | Baird | Maintains | Outperform | $113 → $115 |
| 4 Aug 2026 | Baird | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
TWST appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, Twist Bioscience Corp. returned +367.7% against +12.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 8% of US stocks
Cheaper than 5% of US stocks
Cheaper than 96% of US stocks
Higher than 73% of US stocks
Higher than 62% of US stocks
Higher than 65% of US stocks
Higher than 19% of US stocks
Higher than 13% of US stocks
Higher than 27% of US stocks
Higher than 24% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Twist Bioscience Corp. has a market value of $9.6B and an enterprise value of $9.1B.
Revenue in the twelve months to 30 June 2026: $431.8M. The latest quarter grew 23.2% year on year.
Net income over the same four quarters: −$136.7M, a −31.7% net margin.
Diluted earnings per share, trailing twelve months: $−2.22.
Free cash flow in the twelve months to 30 June 2026: −$93.2M.
Twist Bioscience Corp. spent $18K on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: −111.8×; forward P/E: −363.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Twist Bioscience Corp. employs 979 people — $441K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Twist Bioscience Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Artisan Mid Cap Fund reported a negative absolute return in Q3 2026 but outperformed the Russell Midcap Growth Index. It added Manhattan Associates, Okta and Clean Harbors, and exited Monolithic Power Systems, FTAI Aviation and Ionis Pharmaceuticals.
Why it matters — The excerpt does not mention Twist Bioscience, so it provides no direct update about TWST.
Twist Bioscience said it will report fiscal 2026 fourth-quarter and full-year results before the market opens on November 12, 2026. The company plans an analyst and investor conference call and live webcast at 8:00 a.m. Eastern Time to discuss the results and provide an update.
Why it matters — TWST watchers can note the scheduled date and time for the company’s financial results and update.
Twist Bioscience was among the top contributors to the Alger Small Cap Focus Fund’s performance in Q3 2026.
Why it matters — The update identifies TWST as a positive contributor to the fund’s quarterly performance.
In Q3 2026, Twist Bioscience was among the top contributors to the Polen 5Perspectives Small-Mid Growth Composite Portfolio’s relative performance. The portfolio returned -12.5% net of fees, compared with -10.4% for the Russell 2500 Growth Index.
Why it matters — TWST watchers may note that the portfolio identified Twist Bioscience as a relative-performance contributor during the quarter.
Danaher announced plans to launch its first AI-powered autonomous laboratory, scheduled to operate at commercial scale in early 2027. The announcement marks a development in life science automation, though trading in Danaher shares barely moved that day.
Why it matters — TWST watchers may find the news relevant as an example of AI adoption and automation in the life sciences sector.
The 13 Wall Street analysts covering Twist Bioscience Corp. have a median 12-month price target of $189, with estimates ranging from $45 to $215. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Twist Bioscience Corp., 9 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Twist Bioscience Corp. 70 out of 100 across roughly 4,600 US stocks as at 26 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 26 Oct 2026, Twist Bioscience Corp. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (92 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +17.9% from the last close, and Ticker Nerd's factor model ranks Twist Bioscience Corp. 70 out of 100 as at 26 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Twist Bioscience Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TWST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $45 to $215 over the next 12 months.
Twist Bioscience Corp. returned +367.7% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Twist Bioscience Corporation is a synthetic biology company that develops and sells DNA-based products for research and commercial applications. Twist Bioscience Corporation’s portfolio includes synthetic genes, gene fragments, oligonucleotide pools, and antibody libraries used in therapeutic discovery, diagnostics, agriculture, industrial biotechnology, and academic research.
The most recent item we track (Seeking Alpha, 27 Oct 2026): "Artisan Mid Cap Fund Q3 2026 Portfolio Update". Artisan Mid Cap Fund reported a negative absolute return in Q3 2026 but outperformed the Russell Midcap Growth Index. It added Manhattan Associates, Okta and Clean Harbors, and exited Monolithic Power Systems, FTAI Aviation and Ionis Pharmaceuticals.
Twist Bioscience Corporation is a synthetic biology company that develops and sells DNA-based products for research and commercial applications. Twist Bioscience Corporation’s portfolio includes synthetic genes, gene fragments, oligonucleotide pools, and antibody libraries used in therapeutic discovery, diagnostics, agriculture, industrial biotechnology, and academic research. The company also supports advanced workflows such as targeted next-generation sequencing, CRISPR gene editing, mutagenesis, and DNA data storage. Its proprietary semiconductor-based DNA synthesis platform is designed to produce high-quality synthetic DNA at scale, helping customers move from design to experimentation more efficiently. Twist Bioscience Corporation serves biotechnology, pharmaceutical, industrial, and academic customers across multiple regions, making it an important supplier in the life sciences tools and synthetic biology market.
CEO Dr. Emily Marine Leproust Ph.D. · 979 employees · United States · https://www.twistbioscience.com
